No Data
Shuangcheng Pharmaceutical: Report for the third quarter of 2024
hainan shuangcheng pharmaceuticals (002693.SZ): a net loss of 37.8377 million yuan in the first three quarters.
GeLongHui October 30th | Hainan Shuangcheng Pharmaceuticals (002693.SZ) released the third quarter report for 2024, achieving revenue of 0.127 billion yuan in the first three quarters of the company, a year-on-year decrease of 30.34%; net income attributable to shareholders of the listed company -37.8377 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses -39.9246 million yuan; basic earnings per share -0.0913 yuan.
Is the strongest main theme of this round of market? Mergers and acquisitions continue to be hot, with the "strongest concept stock" closing limit up for 27 consecutive days.
A new round of peak period.
Skyrocketed! 23 halts in 26 days.
A good memory lasts long.
Market rotation between high and low speeds up! The new energy fund track collectively warms up, and the direction of mergers and reorganizations favors the strong.
Track the entire lifecycle of the main sector.
Technology stocks are experiencing another outbreak igniting bullish sentiment in the market, seizing intraday rotation opportunities remains crucial.
Track the entire lifecycle of the main sector.
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some DebtNo Data
No Data
